Treatment guidelines recommend omega-3 with Docosahexaenoic Acid (DHA) and
Eicosapentaenoic Acid (EPA) content not above 85% in patients with high plasma levels of
triglycerides. Since the different up to date formulation of omega-3 available in commerce must be
similar to clinical efficacy and safety, herein, we report the case a 52-year-old woman who presented
clinical inefficacy using Olevia® omega-3 treatment. Clinical evaluation excluded the presence of
intestinal or systemic diseases able to reduce the drug absorption. Switching the therapy from (Olevia®) to an equivalent
omega-3 formulation (Esapent®), we documented a decrease in her plasma triglycerides levels. In order to evaluate a
possible difference between these formulations we performed a single blind in vitro dissolution test using three pills for
each formulation of omega-3 (Olevia®, Esapent® and another one chosen between the several formulations available in
commerce: DOC Generic®) that revealed a significant difference (>20%) in the dissolution time of three different omega-
3 commercially available drug formulation.
Keywords: Omega-3 formulation, clinical efficacy, clinical inefficacy, dissolution time.
Rights & PermissionsPrintExport